Literature DB >> 11922895

Increased effects of C-type natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice.

Melanie Pierkes1, Stepan Gambaryan, Peter Bokník, Suzanne M Lohmann, Wilhelm Schmitz, Regine Potthast, Rita Holtwick, Michaela Kuhn.   

Abstract

OBJECTIVE: The natriuretic peptides (NPs), atrial (ANP), B-type (BNP), and C-type (CNP) natriuretic peptides as well as their respective receptor-guanylyl cyclases (GC-A for ANP and BNP, and GC-B for CNP) are expressed in the heart. However, the local role of NPs in the regulation of cardiac contractility and the mutual interactions of NPs remain controversial. In the present study we evaluated the effects of ANP and CNP on cardiac function of wild-type (GC-A +/+) and GC-A-deficient (GC-A -/-) mice.
METHODS: The effects of NPs and their molecular mechanisms were assessed in the isolated perfused mouse working heart preparation.
RESULTS: In GC-A +/+ hearts, CNP exerted a biphasic action: an immediate increase in inotropy and lusitropy, followed by a slowly developing negative inotropic effect. These effects were mimicked by the cGMP-analogue, 8-pCPT-cGMP. In contrast, ANP did not affect cardiac function. In GC-A -/- hearts, the immediate contractile responses to CNP and 8-pCPT-cGMP were significantly enhanced. CNP increased cardiac cGMP levels and stimulated phospholamban (PLB) phosphorylation; the effect on PLB, but not cGMP, was enhanced in GC-A -/- hearts. In addition, cardiac expression of cGMP-dependent protein kinase (cGK I) was significantly increased in GC-A -/- mice.
CONCLUSION: CNP exerts a biphasic, initially positive inotropic and lusitropic, then negative inotropic effect in isolated working mouse hearts. A putative mechanism contributing to the immediate contractile responses is cGMP/cGK I-dependent phosphorylation of PLB and subsequent activation of the sarcoplasmic reticulum Ca(2+)-pump. ANP has no direct effects on cardiac contractility but chronic absence of its receptor, GC-A, results in increased responsiveness to CNP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11922895     DOI: 10.1016/s0008-6363(01)00543-0

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  25 in total

1.  Study of the regulation of the inotropic response to 5-HT4 receptor activation via phosphodiesterases and its cross-talk with C-type natriuretic peptide in porcine left atrium.

Authors:  S Weninger; J H De Maeyer; R A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-03-17       Impact factor: 3.000

2.  Natriuretic peptide receptors and heart failure: to B or not to B blocked?

Authors:  A J Hobbs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-06       Impact factor: 3.000

3.  Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium.

Authors:  Sabine Weninger; Joris H De Maeyer; Romain A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-03       Impact factor: 3.000

4.  SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardium.

Authors:  L R Moltzau; J M Aronsen; S Meier; C H T Nguyen; K Hougen; Ø Ørstavik; I Sjaastad; G Christensen; T Skomedal; J-B Osnes; F O Levy; E Qvigstad
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

5.  Elevated C-type natriuretic peptide elicits exercise preconditioning-induced cardioprotection against myocardial injury probably via the up-regulation of NPR-B.

Authors:  Jiao Lu; Shan-Shan Pan
Journal:  J Physiol Sci       Date:  2016-08-24       Impact factor: 2.781

6.  Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.

Authors:  Thomas H Langenickel; Jens Buttgereit; Ines Pagel-Langenickel; Maren Lindner; Jan Monti; Knut Beuerlein; Nidal Al-Saadi; Ralph Plehm; Elena Popova; Jens Tank; Rainer Dietz; Roland Willenbrock; Michael Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

Review 7.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

8.  Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I.

Authors:  Kai C Wollert; Sevdalina Yurukova; Ana Kilic; Frank Begrow; Beate Fiedler; Stepan Gambaryan; Ulrich Walter; Suzanne M Lohmann; Michaela Kuhn
Journal:  Br J Pharmacol       Date:  2003-11-10       Impact factor: 8.739

9.  C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise Responses after Heart Failure.

Authors:  Tiankai Li; Heng-Jie Cheng; Nobuyuki Ohte; Hiroshi Hasegawa; Atsushi Morimoto; David M Herrington; William C Little; Weimin Li; Che Ping Cheng
Journal:  J Pharmacol Exp Ther       Date:  2016-03-29       Impact factor: 4.030

Review 10.  Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy.

Authors:  Ines Pagel-Langenickel; Jens Buttgereit; Michael Bader; Thomas H Langenickel
Journal:  J Mol Med (Berl)       Date:  2007-04-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.